Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yiqi Fumai Lyophilized Injection for acute decompensated ischemic heart failure
ChiCTR-IPR-15007396Phase 4Recruiting
- Sponsor
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
- Start
- Sep 2015
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of yiqi fumai in heart failure (HF) and coronary arteriosclerosis (2 arms), sponsored by First Teaching Hospital of Tianjin University of Traditional Chinese Medicine. Primary endpoint: Brain natriuretic peptide. Started Sep 2015; status: recruiting.
02
Drugs
yiqi fumai
03
Conditions
heart failure (HF)coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR-IPR-15007396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15007396.